AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32366199 — intervention group
Group type: EXPERIMENTAL
Intervention: Median household income
Number of subjects: 393430
Study 32366199 — intervention group
Group type: EXPERIMENTAL
Intervention: Average health insurance costs
Number of subjects: 393430
Study 32366199 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity index areas
Number of subjects: 393430
Study 34389506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks)
Number of subjects: 104
Study 34389506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 32084562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 44
Study 32084562 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical control
Number of subjects: 44
Study 35695687 — intervention group
Group type: EXPERIMENTAL
Intervention: Kovir capsule
Number of subjects: 66
Study 35695687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34239935 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Recreational Volleyball (MRV)
Number of subjects: 34
Study 34239935 — intervention group
Group type: COMPARATOR
Intervention: Recreational Volleyball (RV)
Number of subjects: 34
Study 33036674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurectomy
Number of subjects: 100
Study 33036674 — intervention group
Group type: COMPARATOR
Intervention: Nerve Sparing
Number of subjects: 100
Study 34875625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (BIC)
Number of subjects: 19
Study 34875625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Citrate (CIT)
Number of subjects: 19
Study 34875625 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 19
Study 32269011 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF-assisted fat graft
Number of subjects: 50
Study 32269011 — intervention group
Group type: COMPARATOR
Intervention: Fat graft only
Number of subjects: 50
Study 32090383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratesticular mepivacaine
Number of subjects: 34
Study 32090383 — intervention group
Group type: COMPARATOR
Intervention: Intratesticular lidocaine
Number of subjects: 34
Study 33407792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (supervised, outpatient, twice weekly for 8 weeks)
Number of subjects: 190
Study 33407792 — intervention group
Group type: COMPARATOR
Intervention: Usual care without specific instructions to exercise
Number of subjects: 190
Study 36199946 — intervention group
Group type: EXPERIMENTAL
Intervention: In-room brachytherapy (IRBT)
Number of subjects: 294
Study 36199946 — intervention group
Group type: COMPARATOR
Intervention: Out-room brachytherapy (ORBT)
Number of subjects: 294
Study 36199946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IRBT and ORBT
Number of subjects: 294
Study 35319625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Instructional Guide for Clinical Reasoning
Number of subjects: 51
Study 34022445 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal robotic group (X-R)
Number of subjects: 203
Study 34022445 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal laparoscopic group (X-L)
Number of subjects: 203
Study 34022445 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal laparoscopic group (T-L)
Number of subjects: 203
Study 34022445 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal robotic group (T-R)
Number of subjects: 203
Study 33080934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup Red Raspberry (RRB) per day for 4 weeks
Number of subjects: 35
Study 33080934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup Red Raspberry (RRB) with 8 g Fructo-Oligosaccharides (FOS) per day for 4 weeks
Number of subjects: 35
Study 35916800 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (1,000 mg daily for 10 months)
Number of subjects: 165
Study 35916800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D (1.5 mL daily for 10 months)
Number of subjects: 165
Study 35916800 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (hydroxyurea + Ibuprofen)
Number of subjects: 165
Study 35406087 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant (NZBC) extract
Number of subjects: 12
Study 35406087 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 32380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood tumor mutational burden (bTMB)
Number of subjects: 424
Study 32380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in KEAP1
Number of subjects: 424
Study 34420942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET, n=12)
Number of subjects: 24
Study 32679209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen immunotherapy (ILIT) with 3 injections and a booster 1 year later
Number of subjects: 36
Study 32679209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen immunotherapy (ILIT)
Number of subjects: 36
Study 32679209 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 36
Study 32679209 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection
Number of subjects: 36
Study 36482103 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (atezo-chemo)
Number of subjects: 68
Study 36482103 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (placebo-chemo)
Number of subjects: 68
Study 33141603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego depletion group (self-control manipulation through a written transcription task)
Number of subjects: 262
Study 33141603 — intervention group
Group type: COMPARATOR
Intervention: Control group (transcribed text normally)
Number of subjects: 262
Study 32480437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPT with LEGA-Kid
Number of subjects: 30
Study 32480437 — intervention group
Group type: COMPARATOR
Intervention: Manual CPT
Number of subjects: 30
Study 33694229 — intervention group
Group type: COMPARATOR
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 96
Study 33694229 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal bacteriotherapy
Number of subjects: 96
Study 33694229 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 96
Study 33125037 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-CAM algorithm
Number of subjects: 300
Study 33125037 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-mCAM algorithm
Number of subjects: 300
Study 34973179 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 119
Study 34973179 — intervention group
Group type: COMPARATOR
Intervention: Iodine
Number of subjects: 119
Study 33783497 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with behavioural impact optimization
Number of subjects: 1401
Study 33783497 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain feedback
Number of subjects: 1401
Study 33783497 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1401
Study 33783497 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural impact group
Number of subjects: 1401
Study 36069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 64
Study 36069479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 34537624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP)
Number of subjects: 80
Study 34537624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 80
Study 34537624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 80
Study 34537624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AVP and OXT
Number of subjects: 80
Study 34989174 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC-21 1 mg/kg
Number of subjects: 40
Study 34989174 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC-21 3 mg/kg
Number of subjects: 40
Study 34989174 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC-21 10 mg/kg
Number of subjects: 40
Study 34989174 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC-21 20 mg/kg
Number of subjects: 40
Study 34989174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34858513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha SR (300 mg)
Number of subjects: 130
Study 34858513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 35644107 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3-6-9 supplementation
Number of subjects: 31
Study 35644107 — intervention group
Group type: COMPARATOR
Intervention: Canola oil placebo
Number of subjects: 31
Study 32538005 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture therapy combined with exercise re-learning rehabilitation therapy
Number of subjects: 90
Study 32538005 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 90
Study 35379469 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified biblock MAA with elastics
Number of subjects: 20
Study 35379469 — intervention group
Group type: COMPARATOR
Intervention: Monoblock MAA
Number of subjects: 20
Study 34591105 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine with information on effectiveness at preventing death from COVID-19
Number of subjects: 2556
Study 34591105 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine with information on overall effectiveness at preventing symptomatic transmission
Number of subjects: 2556
Study 34591105 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson & Johnson vaccine with information on effectiveness at preventing death from COVID-19
Number of subjects: 2556
Study 34591105 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson & Johnson vaccine with information on overall efficacy at preventing symptomatic infection
Number of subjects: 2556
Study 32855874 — intervention group
Group type: EXPERIMENTAL
Intervention: InVitria
Number of subjects: 140
Study 32855874 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand technique
Number of subjects: 140
Study 32855874 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand technique (senior surgeons)
Number of subjects: 140
Study 32855874 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand technique (junior surgeons)
Number of subjects: 140
Study 32855874 — intervention group
Group type: EXPERIMENTAL
Intervention: InVitria (senior surgeons)
Number of subjects: 140
Study 32855874 — intervention group
Group type: EXPERIMENTAL
Intervention: InVitria (junior surgeons)
Number of subjects: 140
Study 35314014 — intervention group
Group type: EXPERIMENTAL
Intervention: CUPS program (integrated nutrition and mathematics curriculum)
Number of subjects: 18
Study 37421852 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO (rich oleocanthal and oleacein extra virgin olive oil)
Number of subjects: 91
Study 37421852 — intervention group
Group type: COMPARATOR
Intervention: OO (common olive oil)
Number of subjects: 91
Study 32062728 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized antipsychotic dose reduction
Number of subjects: 20
Study 32062728 — intervention group
Group type: COMPARATOR
Intervention: Continuous maintenance treatment
Number of subjects: 20
Study 36161830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (induced group)
Number of subjects: 367
Study 36161830 — intervention group
Group type: COMPARATOR
Intervention: Sham (native group)
Number of subjects: 367
Study 33403878 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC measurement with different reagents and instruments (CysC reagent: Whitman, Nanjing, China)
Number of subjects: 63
Study 33403878 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects with RF concentration <11.1 IU/mL)
Number of subjects: 63
Study 32749561 — intervention group
Group type: COMPARATOR
Intervention: Mechanical brushing (MB)
Number of subjects: 38
Study 32749561 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of mechanical brushing with oral irrigation (WP)
Number of subjects: 38
Study 32021150 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training and virtual reality training (ET+VR)
Number of subjects: 106
Study 32021150 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training (VR)
Number of subjects: 106
Study 32021150 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise training (ET)
Number of subjects: 106
Study 35859328 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Number of subjects: 130
Study 35859328 — intervention group
Group type: COMPARATOR
Intervention: Control (rhG-CSF when WBC < 2.0 × 10^9/L or ANC < 1.0 × 10^9/L)
Number of subjects: 130
Study 32255178 — intervention group
Group type: EXPERIMENTAL
Intervention: PASS group
Number of subjects: 60
Study 32255178 — intervention group
Group type: COMPARATOR
Intervention: MBT group
Number of subjects: 60
Study 35285851 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessible care
Number of subjects: 167
Study 35285851 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 167
Study 36470777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training (including digital operating system training, music therapy, aerobic training, and mental health intervention) for 6 months
Number of subjects: 136
Study 36470777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training
Number of subjects: 136
Study 33740084 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Number of subjects: 72
Study 33740084 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 72
Study 32090123 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix 50
Number of subjects: 102
Study 32090123 — intervention group
Group type: COMPARATOR
Intervention: Novo Mix 30
Number of subjects: 102
Study 35572853 — intervention group
Group type: EXPERIMENTAL
Intervention: LT3 monotherapy
Number of subjects: 59
Study 35572853 — intervention group
Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 59
Study 35572853 — intervention group
Group type: EXPERIMENTAL
Intervention: LT3 treatment
Number of subjects: 59
Study 35572853 — intervention group
Group type: COMPARATOR
Intervention: LT4 treatment
Number of subjects: 59
Study 34420980 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen treatment
Number of subjects: 22
Study 34420980 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) external controls
Number of subjects: 22
Study 34420980 — intervention group
Group type: COMPARATOR
Intervention: Natural history study patients
Number of subjects: 22
Study 32584065 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized planned missingness design in daily diary study
Number of subjects: 1300
Study 32584065 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine randomization of item display and order, timing and frequency of measurement
Number of subjects: 1300
Study 34979943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled paravertebral-block analgesia (PBA)
Number of subjects: 338
Study 34979943 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PIA)
Number of subjects: 338
Study 33999547 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion during cardiac surgery
Number of subjects: 4770
Study 33999547 — intervention group
Group type: COMPARATOR
Intervention: No left atrial appendage occlusion during cardiac surgery (control)
Number of subjects: 4770
Study 32836220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept treatment (1 dose)
Number of subjects: 125
Study 35029235 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based circuit exercise
Number of subjects: 82
Study 35029235 — intervention group
Group type: COMPARATOR
Intervention: Conventional circuit exercise
Number of subjects: 82
Study 33475403 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive clip
Number of subjects: 60
Study 33475403 — intervention group
Group type: COMPARATOR
Intervention: Neutral clip
Number of subjects: 60
Study 34809573 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg with bupivacaine 0.25% 40 ml (Group TAPD)
Number of subjects: 58
Study 34809573 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 40 ml (Group TAPA)
Number of subjects: 58
Study 32129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus rivaroxaban (2.5 mg b.i.d.)
Number of subjects: 30
Study 32129681 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 mg q.d.)
Number of subjects: 30
Study 35834470 — intervention group
Group type: EXPERIMENTAL
Intervention: Engager intervention (one-to-one support)
Number of subjects: 24
Study 35010961 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3 per day (VDD)
Number of subjects: 100
Study 35010961 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 per month (VDM)
Number of subjects: 100
Study 35010961 — intervention group
Group type: COMPARATOR
Intervention: Nothing (Control - CON)
Number of subjects: 100
Study 36082423 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention
Number of subjects: 69
Study 36082423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 34238526 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar dielectric transmission of pulsed electromagnetic fields (PEMF)
Number of subjects: 24
Study 34238526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32947455 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Exercise Therapy (GET)
Number of subjects: 111
Study 32947455 — intervention group
Group type: COMPARATOR
Intervention: Self-Organized Activity (SOA)
Number of subjects: 111
Study 35116266 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Number of subjects: 129
Study 35116266 — intervention group
Group type: COMPARATOR
Intervention: Pelvic-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Number of subjects: 129
Study 32705821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 32
Study 32705821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34011351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 120
Study 34011351 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 120
Study 34011351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36294019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Counselling combined with Unconditional Cash Transfer (NC + UCT)
Number of subjects: 255
Study 33901941 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month web-based transitional care program
Number of subjects: 116
Study 33901941 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 32843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle therapy
Number of subjects: 92
Study 32843084 — intervention group
Group type: COMPARATOR
Intervention: Fire needle control therapy
Number of subjects: 92
Study 33347022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine for 8 weeks
Number of subjects: 0
Study 33347022 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 33419261 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 30
Study 33419261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34256014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 36
Study 34256014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fermented-food diet
Number of subjects: 36
Study 34931438 — intervention group
Group type: EXPERIMENTAL
Intervention: pTGV prediction model
Number of subjects: 181
Study 33710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ethnography analysis of online posts
Number of subjects: 1867
Study 33710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Online communities for support
Number of subjects: 1867
Study 33710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ethnography
Number of subjects: 1867
Study 33710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to prior work
Number of subjects: 1867
Study 34826819 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (parecoxib injection and subsequent loxoprofen tablets)
Number of subjects: 202
Study 32960662 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐days‐a‐week accelerated postoperative radiotherapy (p‐CAIR)
Number of subjects: 111
Study 32960662 — intervention group
Group type: COMPARATOR
Intervention: postoperative radio‐chemotherapy (p‐RTCT)
Number of subjects: 111
Study 36332959 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotive and educational seminars on medical ethics
Number of subjects: 419
Study 36332959 — intervention group
Group type: COMPARATOR
Intervention: General medical topics seminars (Control)
Number of subjects: 419
Study 35193165 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the heat (40°C, 52% relative humidity)
Number of subjects: 13
Study 35193165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna (55°C, 54% relative humidity)
Number of subjects: 13
Study 35193165 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (40°C)
Number of subjects: 13
Study 35193165 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral water immersion (36.5°C)
Number of subjects: 13
Study 35193165 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes of heat
Number of subjects: 13
Study 32107889 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CAP-B)
Number of subjects: 221
Study 32107889 — intervention group
Group type: COMPARATOR
Intervention: Observation until first disease progression (PD1)
Number of subjects: 221
Study 35361348 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sleep restriction (4 hour sleep opportunity)
Number of subjects: 12